Increasing evidence implicates cerebral microvascular dysfunction in the pathophysiology of 16 numerous central nervous system pathologies, including stroke. Understanding the molecular 17 alterations in cerebral microvessels in these conditions will provide original opportunities for 18 scientific investigation at the pre-clinical and clinical levels. In this study, we conducted a novel 19 genome-wide transcriptomic analysis of microvessels in a mouse model of transient focal 20 cerebral ischemia. Using a publicly available human ischemic stroke dataset, we identified 21 shared alterations in our microvessel dataset with implications for human pathophysiology. 22
From this unbiased analysis, we report predicted alterations in inter-and intra-cellular signaling, 23 emphasizing perturbations in genes involved in blood brain barrier function, endothelial cell 24 activation and metabolism. Furthermore, our study unveiled previously unreported gene 25 expression changes associated with altered sphingolipid metabolism. Altogether, our results 26 have identified microvessel-specific transcriptomic changes in a number of translationally 27 relevant pathways that support the targeting of these pathways in preclinical studies. The data 28 shared here provide a resource for future investigation of translationally relevant pathways in 29 ischemic stroke.
INTRODUCTION 31
Despite many decades of research, stroke is still a leading cause of mortality and disability 32 worldwide [1, 2] . While stroke research has focused largely on development of neuroprotective 33 agents, none of these drugs unequivocally showed an improvement in clinical outcomes [3, 4] . 34
Thus, there is a need to develop novel therapeutic strategies [5] . There is increasing evidence 35 that cerebral microvascular dysfunction plays a critical role in the exacerbation of neurovascular 36 injury in stroke [6] [7] [8] [9] [10] [11] [12] [13] [14] . The cerebrovascular endothelium, in coordination with pericytes [15, 16] 37 and astrocytes[17] plays a critical role in the maintenance of the blood brain barrier (BBB). As 38 the primary barrier between systemic blood supply and the central nervous system, it has great 39 therapeutic potential [18] [19, 20] . 40
Stroke induced alterations in BBB integrity and function are important contributors to brain 41 injury related to hypoxia and neuroinflammation [21] . In the acute phase of stroke, pro-42 inflammatory cytokines (TNF-α, IL-1β) are released and trigger the induction of matrix 43 metalloproteinases 3 and 9 (MMP-3/MMP-9) that degrade the basal lamina and contribute to 44 endothelial activation and BBB permeability [22] . BBB dysfunction exacerbates neurovascular 45 ischemic injury by allowing the entrance of neurotoxic plasma components into the brain 46 parenchyma, increasing intra-cerebral pressure with the risk of brain herniation and vessel 47 compression, further compromising blood flow to the brain [6, 7, 10, 23, 24]. Endothelial 48 activation is marked by dysregulated endothelial function culminating in microvascular 49 thrombosis and tissue damage with progressive cell death. The pathways leading to and 50 resulting from endothelial dysfunction in ischemia require extensive investigation to broaden our 51 understanding of the molecular mechanisms governing disease progression. By expanding our 52 comprehension of the underlying biology at the neurovascular level, we can develop potential 53 therapeutics for clinical intervention. There is an increasingly dire need for novel targeted 54 approaches to prevent BBB disruption in the acute and long-term stroke-related 55 pathophysiology. 56
In order to expand our understanding of how cerebral microvascular dysfunction 57 contributes to ischemic pathology, in the present study, we conducted an unbiased experiment 58
RESULTS 71
Transcriptomic changes in cerebral microvessels after tMCAO 72
In order to examine gene expression changes at the neurovascular level, microvessels 73 were isolated from the cerebral cortices of mice subjected to transient middle cerebral artery 74 occlusion (tMCAO) or sham surgery ( Figure 1A) . This protocol was completed as previously 75 described [25] . RNA was isolated from these microvessels and sequenced on an Illumina 76 platform (n=4). Outliers were excluded similarly across all samples and tMCAO samples 77 clustered with similar gene expression patterns (Supplemental Figure 1) . Interestingly, a mild 78 subgrouping within sham microvessels was observed (Supplemental Figure 1C -D). General 79 examination of transcript expression alterations revealed 18,491 out of 32,129 genes were 80 altered, of which 6,291 genes were significant (Table 1 ; p<0.05). From these significant 81 transcripts, 854 genes had a log fold change of greater than 1 while 837 genes had a log fold 82 change of less than -1 ( Figure 1B ). Other RNA types were also significantly altered and these 83 results are summarized in Table 1 . 84
Cerebral microvessels are composed of endothelial cells, pericytes, and astrocytic end 85 foot processes ( Figure 1A) . In order to examine the extent to which the cellular composition of 86 the microvessels was altered after tMCAO, gene expression markers of these cell types were 87 assessed ( Figure 1C ). In the RNA-sequencing dataset, the expression levels of these cell-88 identity markers remained insignificantly changed, whereas markers of neuroinflammation 89 including glial fibrillary acidic protein (Gfap) and e-selectin (Sele) were significantly induced in 90 microvessel preparations after tMCAO ( Figure 1C ). Similarly, qPCR validation of cell markers 91 for pericytes (platelet derived growth factor receptor-beta (Pdgfr-beta) and CD45), astrocytes 92 (aquaporin 4 (Aqp4)) and endothelial cell markers (zona occludens 1 (ZO-1)/tight junction 93 protein 1 (Tjp1)) resulted in insignificant differences between sham and tMCAO microvessels 94
To identify the functional consequences of gene expression changes after tMCAO, we 96 performed downstream effects (DE) analysis on a subset of the 6,291 significantly altered genes 97 (with a log2 fold change (log2 FC) cut off of < -0.5 and > 0.5) using Ingenuity Pathway Analysis 98
(IPA). This DE analysis included Disease and Function, Canonical Pathway, and Upstream 99
Regulator analyses that were used to identify predicted alterations in various functional and 100 molecular categories based on gene expression alterations. Disease and Function analysis 101 predicted alterations in various biological processes such as behavior, cell-to-cell signaling and interaction, central nervous system development and function, cancer, organismal injury, and 103 neurological diseases ( Figure 1D ). Canonical Pathway analysis predicted positive pathway 104 activation in eukaryotic translation initiation factor 2 (EIF2) and neuroinflammation signaling 105 ( Figure 1E ). In contrast, predicted inhibited pathways shared downstream alterations related to 106 G-coupled protein receptor (GPCR) signaling (ex: Gai, G Beta Gamma, and cAMP-mediated 107 signaling) and calcium signaling (ex: CREB, Dopa-DARPP32, and Glutamate Receptor 108 signaling) ( Figure 1E ). Due to the strength of predicted EIF2 activation indicating a potential halt 109 in protein translation, we also examined the endoplasmic reticulum (ER) stress pathway. ER 110 stress was predicted to be increased with implications for apoptosis (increased transcripts of 111 caspase 3 and 7 (Casp3/7) and tumor necrosis factor (TNF) receptor associated factor 2 112 (Traf2)) along with decreased protein translation (Eif2). Further, we also examined the predicted 113 upstream regulators affected after tMCAO ( Figure 1E ). The top five predicted upstream 114 regulators were a part of following molecular categories: transcriptional regulators (21.25%), 115 enzymes (13.75%), kinases (8.63%), transmembrane receptors (7.38%), and GPCRs (5.5%). 116
These results highlight the variety of molecular changes in the microvasculature after 117 tMCAO. Neuroinflammation in these microvessel preparations is associated broad changes in 118 ER functioning, calcium, and GPCR signaling that is predictive of both transcriptomic and 119 metabolic changes at the cellular level after tMCAO. 120
Translational relevance of microvessel-associated transcriptome changes 121
As many transcriptomic alterations were observed in microvessel preparations after 122 tMCAO, we next sought to specifically examine how these changes related to human disease. 123
To this end, the WebGestalt tool was used to perform gene set enrichment analysis (GSEA) of a 124 priori defined gene sets related to mouse phenotype and human disease. For mouse phenotypic 125 (Supplemental File 1). Of interest, markers of endothelial cell activation including matrix 136 metalloproteinase 9 (Mmp9), Intercellular Adhesion Molecule 1, (Icam1), and TNF family 137 members were also positively enriched in these disease categories. Interestingly, genes 138 involved with more neurological diseases and function were significantly and negatively 139
enriched. 140
Additional analyses were completed using the Disgenet and OMIM databases for human 141 disease ontology and produced comparable results (Supplemental Figure 3) . These results 142 highlight the enrichment of inflammatory and neurological disease categories in microvessel-143 associated gene expression changes after tMCAO. Additionally, these comparisons provide 144 further support for the relevance of our microvessel model in capturing these aspects of stroke 145 pathology. 146
Comparison of mouse microvessels to human lesion samples after ischemia 147
In an effort to understand the specific changes in gene expression relevant to human 148 stroke, we conducted a direct comparison of our microvessel dataset with a publicly-available 149 dataset containing RNA-sequencing data of lesion-site samples from patients post-stroke. 150
Further information on this dataset is summarized in Supplementary Table 1 . Human samples in 151 this dataset included tissue from cortical lesion sites of patients with advanced age (67-74 152 years) and a history of non-fatal ischemia within the last 5 years (GSE56267). 153
Initial comparison of these datasets reveal 541 shared genes, accounting for 8.6% of the 154 microvessel dataset and 35.1% of the human dataset ( Figure 3A) . A heatmap of the Z-scores of 155 the log2FC for these genes is represented in Figure 3B . To further investigate the how these 156 541 genes may have related one another, we performed k-means clustering to divide these 157 genes into 5 distinct clusters (Supplemental Figure 4A and 4B). As could be expected, these 158 distinct clusters were associated with distinct aspects of the shared gene expression patterns 159 between the mouse microvessels and human lesion sites. For example, while clusters 3 and 4 160 both contained genes involved in inflammation, cluster 3 contained general markers of this 161 response (including genes transcribing TNF-family members, NF-kb, and chemokines) and 162 cluster 4 contained 18 vascular disease specific genes involved in inflammation (including heme 163 oxygenase 1 (Hmox1), serpin e family member 1 (Serpine1), pentraxin-related protein 3 (Ptx3), 164 tissue inhibitor of metalloproteinase 1 (Timp1), and CD44) ( Figure 3B , Supplemental Figure 4C ). 165
Cluster 5 contained negatively enriched genes implicated in neurotransmission and metabolism. 166
Additionally, these clusters corresponded to previously defined diseases with separate clusters 167 containing genes enriched for inflammation (cluster 3), central nervous system (cluster 5), and 168 vascular disease (cluster 4) (Supplemental Figure 4D ). These results highlight the functional 169 compartmentalization of the gene alterations shared between our mouse microvessel model 170 and human lesion sites. 171
Further, the 541 genes shared between the human lesions and microvessels were 172 expressed in a highly similar manner ( Figure 3C ; r = 0.76). Functional analysis with of these 173 genes predicted multiple canonical pathways involved in neuroinflammation to be significantly 174 upregulated while g-coupled protein receptor (Protein Kinase A) and calcium dependent 175 signaling processes (Dopa-DARPP) were predicted as significantly suppressed ( Figure 3D ). As 176 expected, we then see that genes involved in Neuroinflammation (r = 0.86, p < 0.0001, n = 27) 177
and Protein Kinase A (r = 0.87, p < 0.00011, n = 25) were similarly expressed across both 178 datasets (Supplemental File 2). While gene expression in the Dopa-DARPP category as a 179 whole was not correlated (r = 0.30, p = 0.31, n = 13), if we removed the dopamine specific 180 genes to highlight the calcium and g-protein coupled receptor signaling components we saw a 181 dramatic correlation of expression between mouse microvessels and human lesion sites (r = 182 0.98, p = 0.0006, n = 6). These removed genes included voltage-gated potassium channels 183 and DARPP32-specific targets not relevant to microvessel cell types (Supplemental File 2). 184
These findings further highlight the conserved alteration of these inflammation and 185 metabolic pathways in ischemic human lesions and mouse microvessels. Given these results, 186
we interpret that the relevance of these microvessel-associated changes to human 187 pathophysiology may lie largely in the disruption of the BBB. 188
Ischemia-induced endothelial cell activation alters transcripts related BBB function in 189 cortical microvessels 190
In order to more closely examine BBB-related transcriptomic alterations after tMCAO 191 and stroke, we included 34 genes related to endothelial cell activation and BBB function and 192 maintenance ( Figure 4A ). Expression of these genes was significantly correlated between 193 mouse microvessels and human lesion-sites after stroke ( Figure 4B ). Molecules involved in 194 maintaining BBB and endothelial cell function are exciting potential targets in neurovascular 195 disease and we observed that several of these genes (including Hmox1, Serpine1, CD44, 196 gardner-rasheed feline sarcoma viral (Fgr), and vitamin D receptor (VDR)) were similarly 197 induced after tMCAO in mice and chronically post-stroke in humans ( Figure 4B ). Further, 198 endothelial cell activation indicated by robust Sele induction was validated in qPCR ( Figure 4C ).
Subsequent validation of some of these translationally-relevant targets revealed novel 200
genes altered in microvessel preparations after tMCAO. Of interest, transcriptional changes in 201 the family of angiopoietins 1/2 (Angpt1/2) and their receptor, tyrosine-protein kinase receptor 202 (TEK), were validated by qPCR. While the transcriptional difference in Angpt1 was insignificant, 203
Angpt2 transcript was significantly induced in the microvessel preparations post-tMCAO ( Figure  204 4D). Tek, the gene that transcribes the Tie2 receptor for Angpt1/2, was also down regulated 205 after tMCAO ( Figure 4E) . 206
In addition, we also analyzed some of critical players of wingless (WNT) signaling in the 207 context of BBB maintenance and function. qPCR-based validation revealed significant down 208 regulation in the mRNA levels of g-protein coupled receptor 124 (Gpr124) and adenomatosis 209 polyposis coli down-regulated 1 (Apcdd1) with an insignificant effect on low density lipoprotein 210 receptor-related protein 1 (Lrp1) mRNA levels in tMCAO microvessels ( Figure 4F ). 211
Additional analysis of the 541 shared genes between mouse microvessels and human 212 lesion-sites revealed 68 genes that were existing drug targets (Supplemental Figure 5 ). This list 213 contained several endothelium-associated genes, including Hmox1 and Serpine1, which were 214 robustly shared between the two datasets. The strong induction of these two specific transcripts 215 was validated in microvessels after tMCAO by qPCR ( Figure 4G -I). Hmox1 and Serpine1 are of 216 high interest as possible novel and druggable targets for the microvasculature and have had 217 promising experimental and clinical outcomes for stroke (Ref) . Thereafter, we sought to validate 218 the enrichment of the selected BBB maintenance and function-associated targets in the 219 microvessel preparations. We performed qPCR quantification of Angpt1/2, Tek, Lrp1, Gpr124, 220
Apcdd1, plasmalemma vesicle-associated protein (Plvap), Serpine 1 and Hmox1 transcripts in 221 the total RNA extracted from whole brain, cortex, and isolated microvessels of naïve mice. 222
These genes were significantly enriched in the microvessels when compared to whole brain and 223 cortex samples suggesting their potential relevance in microvessel-specific functions associated 224 with the maintenance and proper functioning of the BBB ( Figure 5A -E). 225
These results support and emphasize the importance and relevance of the 226 neurovasculature to stroke and highlight the potential of targeting microvessel and endothelial 227 cell function in humans. While many of these transcript alterations have been described to play 228 a role in BBB maintenance and function, how these genes are regulated upon injury was still 229 previously unknown. The observed conservation of pathways related to endothelial cell 230 activation and BBB integrity between tMCAO microvessels and human brain samples after 231 stroke strongly support the principle that these changes at the neurovasculature level are crucial 232 in sustained pathogenesis after ischemia. 233
Ischemia-associated changes in S1P metabolism and receptor signaling in cerebral 234 microvessels 235
As a novel contributor of endothelial cell activation and BBB function, we decided to 236 examine transcriptomic changes in mediators of sphingolipid metabolism. A succinct summary 237 of this pathway with our qPCR results is represented in Figure 6A and a full heatmap containing 238 125 genes involved in sphingolipid metabolism (GO: 0006665) is available in Supplemental 239 Figure 6A . These 125 genes were expressed in a similar manner between mouse microvessels 240 and human lesion sites ( Figure 6B ). 241
Specifically related to the synthesis of sphingosine, we conducted qPCR validation of 242 selected targets involved. While there were no significant changes in the serine 243 palmitoyltransferase (SPT) inhibitors, ORMDL sphingolipid biosynthesis regulator 1/2/3 244 (Ormdl1/2/3), after tMCAO there was a modest and significant increase in the SPT genes 245 themselves, serine palmitoyltransferase long chain base subunit 1/2/3 (Sptlc1/2/3) ( Figure 6C -246 D). Further, there were no observed differences in the transcripts for sphingosine kinases 1/2 247 (Sphk1/2) or S1P phosphatase 1 (Sgpp1) after tMCAO ( Figure 6E -F). Interestingly, there was a 248 significant elevation of alkaline ceramidase 2 transcript (Acer2) suggesting the potential for an 249 increase in conversion of ceramide to sphingosine ( Figure 6G ). Additionally, while there was a 250 modest increase in S1P lyase 1 (Sgpl1) transcript and no remarkable differences in 251 sphingomyelin phosphodiesterase (Smpd1/2) transcript expression ( Figure 6H -I). To better 252 understand the tissue specificity of S1P metabolism-associated genes we conducted a qPCR-253 based relative enrichment analysis between the total RNA extracted from whole brain, cortex 254 tissue, and cortical microvessels of naïve mice. The genes Orndl1/3, Sptlc1/2/3, Sphk1/2, 255 Sgpp1, Smpd1/2 and Sgpl1 were significantly enriched in the microvessel preparations when 256 compared to whole brain and cortex samples ( Figure 7A -G). Importantly, levels of Acer 2 were 257 significantly and robustly enriched in the microvessel fraction compared to cortex and whole 258 brain ( Figure 7E ). In addition, the mRNA levels of Ormdl2 seem modestly but insignificantly 259 abundant in the microvessel preparations when compared to whole brain tissue ( Figure 7B ). 260
Additional qPCR validation of mRNA transcribing S1P's cognate receptors that mediate 261 sphingolipid signaling was conducted. Significant changes in S1pr1/2/4 were observed in 262 microvessels after tMCAO. Of note, S1pr2 was the most robust and significant receptor alteration, in line with previous data from our lab (Supplemental Figure 6D ). Supplmental 264 analysis of RNA-sequencing data with differential gene expression data overlaid on the 265 sphingosine receptor signaling pathway from IPA is available in Supplemental Figure 6C . This 266 data is further reflected in a heat map to compare these changes in mouse microvessels and 267 human lesion-site samples (Supplemental Figure 6B) . 268
Taken together, we highlight novel transcriptomic alterations in sphingosine metabolism 269 that provide additional support to the investigation of this pathway in stroke. This data suggests 270 the importance of the sphingolipid metabolic axis in the cerebral microvessels that might be 271 essential in the regulation of BBB function. Specifically, Acer2 has emerged as a potential target 272 enriched in the microvessels that warrants further investigation. As a major player in ceramide 273 metabolism, this induction is associated with neuroinflammation-associated endothelial cell 274 activation.
MATERIALS AND METHODS 276

Animals and ischemic model 277
All animal experiments were approved by Weill Cornell Institutional Animal Care and Use 278
Committee. C57/BL6/J (8-10 weeks, male) mice are subjects to transient middle cerebral artery 279 occlusion (tMCAO). During tMCAO surgery, mice were deeply anesthetized with Isoflurane and 280 body temperature was maintained at 37 ˚C with self-regulating heating pad. The flow of middle 281 cerebral artery was temporally occluded with silicon coated intraluminal suture (Doccol, 282 602245PK10Re) for 60 minute and reperfused by withdrawing a suture, as previously described 283
[26]. Animals which unable to walk straight 24 hours after surgery were used for microvessel 284 isolation. 285
Microvessel isolation 286
The cerebral microvessels were isolated as previously described [25] . To minimize cell 287 activation, all procedures were conducted in a cold room. Ipsilateral cortices were homogenized 288 with MCDB131 medium (Thermo Fisher Scientific, 10372019) with 0.5% fatty acid free BSA 289 (Millipore Sigma, 126609). The homogenate was centrifuged at 2000 g for 5 minutes at 4˚C. 290
The pellet was suspended in 15% dextran (molecular weight ~70 kDa, Millipore Sigma, 31390) 291 in PBS and centrifuged at 10000 g for 15 minutes at 4˚C. The pellet was resuspended in 292 MCDB131 with 0.5% fatty acid free BSA and centrifuged at 2000 g for 10 min at 4˚C. The pellet 293 contained the microvessels. 294
RNA extraction from cerebral microvessels 295
Isolated cerebral microvessels were dissolved in appropriate amount of RLT lysis buffer to lyse 296 the multicellular structures. Lysed samples were then loaded onto a column-based shredder 297 (QIAshredder, Qiagen, Germany) and centrifuged (8000g for 2min at room temperature) to 298 eluate the homogenized lysate. Thereafter, the lysate was processed using total RNeasy mini 299 kit (Qiagen, Germany). In brief, the lysate was resuspended in 1:1 volume 70% ethanol and 300 loaded onto extraction column and centrifuged (8000g for 2min) at room temperature. DNase-I 301 digestion was performed on-column for samples with 1U of TURBO-DNase (Invitrogen, 302
ThermoFisher Scientific) and incubated for 15min at room temperature. Then columns were 303 washed with appropriate amount of wash buffer and finally total RNA was eluted using 25-20 µl 304 of nuclease free water. 305
Quality Check of total RNA extracted from cerebral microvessels 307
To ensure the quality of total RNA preparations from the cerebral microvessels, 200ng of total 308 RNA were electrophoresed in 1% Agarose Gel at 80V for 30min at room temperature. Further, 309 100ng of total RNA preps for each sample were analyzed for A260/280 ratios using UV-visible 310 spectroscopy in a microplate format (Varioskan, ThermoFisher Scientific) and subsequently 311 confirmed with a final analysis using Bioanalyzer quantification (Genomics core facility, Weill 312
Cornell Medicine). 313
RNA-sequencing workflow 314
RNA integrity and other quality control measures were performed, as stated above, along with 315 ribosomal RNA depletion before cDNA library preparation. cDNA libraries were made using the 316 
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